China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the Center for Drug Evaluation (CDE) has accepted another clinical trial filing for its VUM02 (human umbilical cord-derived mesenchymal stem cells) for review. The Category 1 therapeutic biologic product is under development as a treatment for acute graft versus host disease (aGvHD).
VUM02: An In-House Developed Cryopreserved Stem-Cell Preparation
VUM02 is an in-house developed cryopreserved stem-cell preparation derived from the umbilical cord tissue of healthy fetuses. The product undergoes isolation, screening, and amplification in vitro before being used as a therapeutic agent. Indicated for the treatment of Grade II to IV aGvHD with failed hormone therapy, VUM02 has previously earned clinical trial approvals for use in acute-on-chronic (subacute) liver failure (ACLF) and moderate or severe acute respiratory distress syndrome (ARDS).
Expanding Clinical Applications of VUM02
The acceptance of VUM02 for review by the CDE marks a significant step in expanding the clinical applications of this stem cell therapy. As a potential treatment for aGvHD, VUM02 joins a growing list of conditions for which it is being investigated, highlighting the versatility and potential efficacy of this therapeutic biologic product in addressing critical unmet medical needs.-Fineline Info & Tech
